The UK and US have finalized a key bilateral deal that will maintain no tariffs on UK drug products going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these key exports will be held at zero for a duration of 36 months.
This deal is in response to recent threats to significantly raise import taxes on branded drug imports, with increases discussed as high as one hundred percent.
"This arrangement with the UK reinforces the international landscape for innovative medicines and brings much-needed fairness to U.S.–U.K. pharmaceutical trade," a release said.
Economic Significance
Drugs represent one of the UK's biggest goods shipped to the America, which is clearly the primary buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of last September, the UK exported medicines totaling £11.1bn to the US. This amount accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards work, increases investment and facilitates the UK to establish itself as a international leader for life sciences," a government official stated.
Key NHS Changes
The deal involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to increase overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be capped at 15%. In the past, rebates topped twenty percent.
Broader Context
The pact comes amid a ongoing dispute between the drug companies and the British authorities over drug pricing and regulatory access.
This friction were heightened by claims that American patients were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or abandoned, while major investments have been pledged toward American operations.
A senior figure stated that the NHS had to invest a greater share on treatments, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
